The association between weight loss medications and cardiovascular complications
Authors' conclusion
Results suggest that utilization of AOMs effectively alleviates the high prevalence of CVD.
Study context
- Population
- Medicare patients with obesity; most common comorbidities hypertension, T2D and hyperlipidemia
- Exposure
- Newly approved antiobesity medications vs no antiobesity medications (AOMs)
- AOMsn = 5,926
- Outcome
- CVD events
Methodological detailsMedicare data 2020–2022, Cox and Aalen regression models
- Medicare data 2020–2022
- Cox and Aalen regression models
Main finding
As reported in the abstract
Any CVD
Risk reduction in any cardiovascular disease (CVD) with AOMs
8%
Observational data: associations, not effects.
Further findings
HF incidence · lower with AOMs
P < 0.0001
AF incidence · lower with AOMs
P < 0.0001
Arrhythmia incidence · lower with AOMs
P < 0.0153
- Peripheral vascular disease incidence · less incidence reported with AOMs
- P < 0.0395
Original publication
The association between weight loss medications and cardiovascular complications. Obesity (Silver Spring). Published 6 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →